Adipose MSC and Their Use in Regenerative Medicine/Biotherapies and Which Regulations Need To Be Followed (25EL-541)

Please note: AABB reserves the right to make updates to this program.

• Educational Track: Scientific
• Topic: Biotherapies
• Intended Audience: CEOs, CFOs, COOs, Directors, Donor Recruitment Staff, Hospitals, Laboratory Staff, Managers/Supervisors, Medical Directors, Physicians, Research Scientists, Scientists, Technologists
• Teaching Level: Advanced, Basic, Intermediate

• Director/Moderator: Vasiliki E. Kalodimou, CABP(H), MSc, PhD, IARMES, Director, Flow Cytometry - Research & Regenerative Medicine Department, IASO Maternity & Research Hospital, Athens, Greece; Assistant Professor, School of Medicine, the European University-Cyprus Ltd. Frankfurt Branch, and Former Acting Chair, School of Medicine at the European University-Cyprus Ltd. Frankfurt Branch; Associate Lecturer - Visiting - Health & Care Management at the Arden University Ltd ("The University"), UK; Board/Committee on Research Ethics at the National Hellenic Research Foundation (Ε.Ι.Ε), IASO, EUC-FRA, ARDEN-UK & E.I.E, Greece/Germany
  Speakers:

  • Dimitrios Tsoukas, MD, Director, Orthopaedic Clinic for Advanced Arthroscopic Sports and Regenerative Surgery MITERA Hospital HH Group; Adjunct Professor, Department of Nutrition and Health Sciences University of Nebraska-Lincoln, Lincoln, NE; Founder and Director, MIOSMED Center ISAKOS, ESSKA and ICRS approved Teaching Center; Founder and Director, Elite Regenerative Clinic Athens, a Lipogems SpA Center of Excellence and Teaching Center, MITERA Hospital HH Group, Greece
  • Paul Schiavo, MD, Founder, CEO and Medical Director, OrthoRegen Premier Regenerative Medicine Clinic, Australia

• Program Description

  The emerging field of regenerative medicine will require a reliable source of stem cells in addition to biomaterial scaffolds and cytokine growth factors. Adipose Mesenchymal stem cells show significant promise in treating autoimmune and neurodegenerative diseases, vascular and metabolic diseases, bone and cartilage regeneration and wound defects. Adipose tissue represents an abundant and accessible source of mesenchymal stem cells with the ability to differentiate along multiple lineage pathways. The isolation, characterization, preclinical and clinical application of adipose-derived mesenchymal stem cells will be discussed analyzing real case studies.

  Learning Objectives

  After participating in this educational activity, participants should be able to:

  • Discuss the requirements for regenerative medicine applications with the use of adipose tissue mesenchymal stem cells (MSC's).
  • Discuss what are adipose tissue mesenchymal stem cells (MSC's) and how we can use them in regenerative medicine.
  • Explain what the MSC's are and how we can characterize them and their applications in regenerative medicine.
  • Define why many scientists/research groups around the globe use MSC's in regenerative medicine.
  • Identify the law/standards for regenerative medicine and adipose MSC's applications.

  Registration

  Registration includes access to both the live and on-demand version of this eCast.

  If you are a facility interested in participating in this eCast, simply complete the Group Viewing registration form and AABB will provide detailed instructions to share with your team approximately one week prior to the live program (each team member to register for the program utilizing a promocode). For single viewers, simply click on the Register button below to register.

  Please note: registration for the live eCast will close 1 hour prior to the eCast start time. If you register after this time, you will receive access to the on-demand eCast when it is available.

  Single Viewer	Register
  Group Viewing	Register

  Continuing Education Credit

  This activity is eligible for one and a half (1.5) continuing education credit/contact hour for Physicians, Nurses (including California-based nursing professionals through CBRN), California Lab Personnel, Florida Lab Personnel and General Participation credit. AABB reserves the right to reduce or increase the number of credits granted based on the final activity duration. For more information on each credit type please visit our Continuing Education Credits webpage.

  There is no financial support for this activity.

  

  In support of improving patient care, this activity has been planned and implemented by the Association for the Advancement of Blood & Biotherapies (AABB) and CME Outfitters, LLC. CME Outfitters LLC. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

  Physicians (ACCME): CME Outfitters, LLC, designates this live activity for a maximum of one and a half (1.5) AMA PRA Category 1 Credit^TM. CME Outfitters, LLC, designates this enduring activity for a maximum of one and a half (1.5) AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  Claiming Credit
  Live Activity - Upon completion of the live activity, you will receive instructions to complete your evaluation, which is necessary to claim credit and receive your certificate of attendance/completion (credit must be claimed by the date provided in the instructions). The evaluation can be found by logging into the AABB Education Platform.

  Enduring Activity - Once the enduring (on-demand) program is available, you will receive instructions to access the AABB Education Platform. Upon completion of viewing the enduring activity, you will need to complete the evaluation, which is necessary to claim credit and receive your certificate of completion (credit must be claimed by the date provided in the AABB Education Platform).

  Program & Credit Expiration Dates:

  • Live Activity Program Date: June 4, 2025; Credit Expiration Date: July 4, 2025
  • Enduring Activity Program Dates: June 4, 2025 – June 3, 2028; Credit Expiration Date: June 3, 2028

  Disclosure Declaration

  It is the policy of CME Outfitters, LLC, and the Association for the Advancement of Blood & Biotherapies to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that the presence of such relationships will have a negative impact on the presentations.

  Disclosures for the planners of this event can be found here. Disclosures for the program faculty, peer reviewers, and CME Outfitters, LLC. personnel are provided at the beginning of the program.

  Faculty Biographies

  Since 2006, Dr. Vasiliki Kalodimou has studied and worked with stem cells from placenta, umbilical cord and adipose tissue, in everyday practice and their applications in regenerative medicine, clinical trials, medical tourism and flow cytometry. Also, Dr. Kalodimou is working in the area of human genetics and population genetics, soluble vitamins and stem cells and their role in human health as well as cellular standards. In addition to collaboration with state universities and pharmaceutical companies on research projects (19), Dr. Kalodimou frequently publishes (49 & 11 books) her findings. She has 2 patents and is a member of AABB involved in many committees as well as an AABB assessor.

  
  

  Dr. Paul Schiavo is a global key opinion leader and pioneer in clinical regenerative medicine in Australia. He is the Founder, CEO and Medical Director of OrthoRegen, a premier regenerative medicine clinic in Australia. Dr. Schiavo completed his medical degree at the University of Queensland in Brisbane, Australia. After his graduation, Dr. Schiavo completed his resident years at the Royal Brisbane and Women’s Hospital. He gained experience in multiple disciplines including Emergency Medicine and Orthopaedic Surgery before changing his specialty path to General Practice/Family Medicine. Dr. Schiavo has a vision of bringing non-surgical regenerative medicine procedures to the community in Australia, to reduce the unnecessary high level of surgery that is taking place. He is a pioneer in medicine 4.0, the integration of digital technologies and biologics in healthcare. He is leading the field in Australia, with his innovative and evidence-based approaches to regenerative medicine and longevity medicine.

  
  

  Dr. Dimitrios Tsoukas is certified by the American Board of Regenerative Medicine ABRM (Diplomat), August 14, 2023. He completed his training at Imagine Regenerative Clinic, Milan, Italy on October 4-5, 2021, with Prof Carlo Tremolada in adipose tissue stem cells with the Lipogems technique. Prof. Tremolada is the Founder of Lipogems an FDA cleared technique. Dr. Tsoukas has internationally published many scientific papers, is a regularly invited speaker at sports medicine and regenerative medicine congresses and instructor at arthroscopic cadaveric courses. He was a global trainer of the American top biotechnology company Harvest- Terumo BCT in adipose tissue derived stem cells after minor belly liposuction that he can perform by himself, after the training he received from Terumo BCT, January 18, 2017, Poland. He has published his results with this technique. He has trained doctors in live surgeries with this technique in Spain, Israel, Azerbaijan and Norway. He is the first orthopaedic surgeon in Greece and in Cyprus who has performed intra articular injections of adipose tissue derived stem cells after belly minor liposuction for arthritic problems using four different techniques: Harvest-Terumo BCT, Arthrex, Lipogems and T-LAB, and the first one in Europe after knee liposuction for the same purpose, according the Lipopras technique of the Spanish Company Proteal.